您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Cefixime
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cefixime
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cefixime图片
CAS NO:79350-37-1
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
头孢克肟是一种抗生素和第三代头孢菌素抗生素,可用于治疗多种细菌感染。
Cas No.79350-37-1
别名头孢克肟; FR-17027; FK-027; CL-284635
化学名(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-[carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Canonical SMILES[H][C@@]1([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)N(C(C(O)=O)=C(C=C)CS1)C2=O
分子式C16H15N5O7S2
分子量453.4
溶解度≤5mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
储存条件Store at 2-8℃, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

MIC: from<0.025 to 25 μg/ml for E. coli, K. pneumoniae, and H. influenzae

Cefixime is a third generation cephalosporin antibiotic.

The cephalosporins, a class of β-lactam antibiotics, are originally derived from the fungus Acremonium.

In vitro: Previous study found that cefixime was more active than cephalexin, cefaclor, and amoxicillin against various gram-negative bacteria. Cefixime was also significantly more active than tested reference drugs against clinical isolates of Klebsiella pneumoniae, Escherichia coli, indole-positive and -negative Proteus species, Providencia species, and Neisseria gonorrhoeae. Moreover, cefixime was active against strains of K. pneumoniae, E. coli, as well as Proteus mirabilis resistant to the reference agents [1].

In vivo: The therapeutic activities of cefixime in mice infected with gram-negative bacilli were found to be far superior to the activities of cephalexin, cefaclor, and amoxicillin, but they were inferior to the activities against infection with Staphylococcus aureus [1].

Clinical trial: Previous study showed that the clinical success was observed in 94% of cefixime-treated patients. At the end of treatment, the overall eradication rate in the cefixime treatment group was 92% and ranged from 76% (cefaclor) to 98% (cefuroxime axetil) in the comparator treatment groups [2].

References:
[1] Kamimura, T. ,Kojo, H.,Matsumoto, Y., et al. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrobial Agents and Chemotherapy 25(1), 98-104 (1984).
[2] Quintiliani R.  Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. Clin Ther. 1996 May-Jun;18(3):373-90; discussion 372.